JPMorgan Cuts TG Therapeutics Price Target to $46, Retains Overweight
JPMorgan analyst Brian Cheng lowered TG Therapeutics’ price target to $46 from $49 on February 2 while maintaining an Overweight rating after updating the investment bank’s valuation model. This adjustment follows TG Therapeutics’ February 6 presentation of adult relapsing multiple sclerosis Briumvi trial data in San Diego.
1. Analyst Price Target Revision
On February 2, JPMorgan analyst Brian Cheng reduced the price target for TG Therapeutics from $49 to $46 per share and maintained an Overweight rating following an updated valuation model. The revision reflects adjusted revenue projections and market penetration assumptions for the company’s immunotherapy portfolio.
2. Briumvi Trial Data Presentation
TG Therapeutics presented phase data for its Briumvi treatment in adult relapsing multiple sclerosis on February 6 at a medical forum in San Diego. The presentation highlighted efficacy metrics and dosing developments for both intravenous and subcutaneous formulations, which could impact market share against competing therapies.
3. Analyst Ratings Consensus
Other Wall Street firms remain bullish: H.C. Wainwright holds a Buy rating citing commercial momentum and expected 2026 catalysts, while TD Cowen reiterated a Buy stance with a $50 price target. These endorsements underscore confidence in upcoming clinical readouts and potential revenue growth.